S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Pfizer Stock Forecast, Price & News

-0.33 (-0.98 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $33.49
50-Day Range
MA: $35.69
52-Week Range
Now: $33.49
Volume41.46 million shs
Average Volume35.65 million shs
Market Capitalization$186.15 billion
P/E Ratio21.61
Dividend Yield4.66%
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Myovant Sciences Ltd.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; a drug discovery collaboration with Sosei Group Corporation; and collaboration with LianBio. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A



Sales & Book Value

Annual Sales$51.75 billion
Cash Flow$3.73 per share
Book Value$11.46 per share


Net Income$16.27 billion


Outstanding Shares5,558,396,000
Market Cap$186.15 billion
Next Earnings Date4/27/2021 (Estimated)


Overall MarketRank

2.58 out of 5 stars

Medical Sector

10th out of 1,962 stocks

Pharmaceutical Preparations Industry

4th out of 772 stocks

Analyst Opinion: 3.1Community Rank: 2.9Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
-0.33 (-0.98 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pfizer (NYSE:PFE) Frequently Asked Questions

Is Pfizer a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Pfizer stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
View analyst ratings for Pfizer
or view top-rated stocks.

What stocks does MarketBeat like better than Pfizer?

Wall Street analysts have given Pfizer a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pfizer wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pfizer's next earnings date?

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Pfizer

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its earnings results on Tuesday, February, 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by $0.04. The biopharmaceutical company had revenue of $11.68 billion for the quarter, compared to analyst estimates of $11.32 billion. Pfizer had a net margin of 17.85% and a trailing twelve-month return on equity of 24.88%. The firm's revenue was up 11.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.55 earnings per share.
View Pfizer's earnings history

How has Pfizer's stock price been impacted by COVID-19?

Pfizer's stock was trading at $32.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PFE shares have increased by 4.1% and is now trading at $33.49.
View which stocks have been most impacted by COVID-19

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Friday, December 11th. Investors of record on Friday, January 29th will be given a dividend of $0.39 per share on Friday, March 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.66%. The ex-dividend date of this dividend is Thursday, January 28th. This is a positive change from Pfizer's previous quarterly dividend of $0.38.
View Pfizer's dividend history

Is Pfizer a good dividend stock?

Pfizer pays an annual dividend of $1.56 per share and currently has a dividend yield of 4.66%. PFE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Pfizer does not yet have a strock track record of dividend growth. The dividend payout ratio of Pfizer is 52.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Pfizer will have a dividend payout ratio of 50.98% next year. This indicates that Pfizer will be able to sustain or increase its dividend.
View Pfizer's dividend history.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY21 earnings guidance on Tuesday, February, 2nd. The company provided earnings per share guidance of $3.10-3.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.97. The company issued revenue guidance of $59.4-61.4 billion, compared to the consensus revenue estimate of $48.51 billion.

What price target have analysts set for PFE?

14 brokers have issued 1-year target prices for Pfizer's stock. Their forecasts range from $24.00 to $53.00. On average, they anticipate Pfizer's share price to reach $39.53 in the next year. This suggests a possible upside of 18.0% from the stock's current price.
View analysts' price targets for Pfizer
or view top-rated stocks among Wall Street analysts.

Who are Pfizer's key executives?

Pfizer's management team includes the following people:
  • Dr. Albert Bourla D.V.M., DVM, Ph.D., Chairman & CEO (Age 59, Pay $5.84M)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 56, Pay $3.36M)
  • Mr. Frank A. D'Amelio, CFO & Exec. VP of Global Supply (Age 63, Pay $3.84M)
  • Dr. Mikael Dolsten, Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical (Age 62, Pay $3.66M)
  • Ms. Jennifer B. Damico, Sr. VP, Controller & Principal Accounting Officer (Age 53)
  • Ms. Lidia L. Fonseca, Exec. VP and Chief Digital & Technology Officer (Age 52)
  • Mr. Charles E. Triano, Sr. VP of Investor Relations
  • Mr. Douglas M. Lankler, Exec. VP & Gen. Counsel (Age 55)
  • Mr. Rady A. Johnson, Exec. VP and Chief Compliance, Quality & Risk Officer (Age 59)
  • Dr. Alexander Rod MacKenzie, Chief Devel. Officer & Exec. VP of Global Product Devel. (Age 61)

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer CEO Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among Pfizer's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), The Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.14%), Northern Trust Corp (1.20%), Bank of New York Mellon Corp (1.17%), Morgan Stanley (0.96%), Charles Schwab Investment Management Inc. (0.76%) and Dimensional Fund Advisors LP (0.73%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Jennifer B Damico, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Ronald E Blaylock and Scott Gottlieb.
View institutional ownership trends for Pfizer

Which institutional investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Lazard Asset Management LLC, Price T Rowe Associates Inc. MD, FIL Ltd, Boston Partners, Alliancebernstein L.P., American International Group Inc., and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Pfizer company stock in the last year include Douglas M Lankler, and Jennifer B Damico.
View insider buying and selling activity for Pfizer
or view top insider-selling stocks.

Which institutional investors are buying Pfizer stock?

PFE stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Bank of New York Mellon Corp, Sanders Capital LLC, Orbimed Advisors LLC, Canada Pension Plan Investment Board, Charles Schwab Investment Management Inc., Stevard LLC, and State of Tennessee Treasury Department. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, Ronald E Blaylock, and Scott Gottlieb.
View insider buying and selling activity for Pfizer
or or view top insider-buying stocks.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $33.49.

How much money does Pfizer make?

Pfizer has a market capitalization of $186.15 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis.

How many employees does Pfizer have?

Pfizer employs 88,300 workers across the globe.

What is Pfizer's official website?

The official website for Pfizer is www.pfizer.com.

Where are Pfizer's headquarters?

Pfizer is headquartered at 235 EAST 42ND STREET, NEW YORK NY, 10017.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.

This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.